You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma
|
|---|---|
| Published in |
Blood, August 2012
|
| DOI | 10.1182/blood-2012-04-426643 |
| Pubmed ID | |
| Authors |
Stephen R. Mattarollo, Alison C. West, Kim Steegh, Helene Duret, Christophe Paget, Ben Martin, Geoffrey M. Matthews, Jake Shortt, Marta Chesi, P. Leif Bergsagel, Michael Bots, Johannes Zuber, Scott W. Lowe, Ricky W. Johnstone, Mark J. Smyth |
| Abstract |
Immunomodulators are effective in controlling hematologic malignancy by initiating or reactivating host antitumor immunity to otherwise poorly immunogenic and immune suppressive cancers. We aimed to boost antitumor immunity in B-cell lymphoma by developing a tumor cell vaccine incorporating α-galactosylceramide (α-GalCer) that targets the immune adjuvant properties of NKT cells. In the Eμ-myc transgenic mouse model, single therapeutic vaccination of irradiated, α-GalCer-loaded autologous tumor cells was sufficient to significantly inhibit growth of established tumors and prolong survival. Vaccine-induced antilymphoma immunity required NKT cells, NK cells, and CD8 T cells, and early IL-12-dependent production of IFN-γ. CD4 T cells, gamma/delta T cells, and IL-18 were not critical. Vaccine treatment induced a large systemic spike of IFN-γ and transient peripheral expansion of both NKT cells and NK cells, the major sources of IFN-γ. Furthermore, this vaccine approach was assessed in several other hematopoietic tumor models and was also therapeutically effective against AML-ETO9a acute myeloid leukemia. Replacing α-GalCer with β-mannosylceramide resulted in prolonged protection against Eμ-myc lymphoma. Overall, our results demonstrate a potent immune adjuvant effect of NKT cell ligands in therapeutic anticancer vaccination against oncogene-driven lymphomas, and this work supports clinical investigation of NKT cell-based immunotherapy in patients with hematologic malignancies. |
Mendeley readers
The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 1% |
| Austria | 1 | 1% |
| Australia | 1 | 1% |
| Israel | 1 | 1% |
| China | 1 | 1% |
| Unknown | 71 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 15 | 20% |
| Researcher | 9 | 12% |
| Student > Master | 8 | 11% |
| Other | 7 | 9% |
| Student > Bachelor | 6 | 8% |
| Other | 17 | 22% |
| Unknown | 14 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 22 | 29% |
| Medicine and Dentistry | 13 | 17% |
| Immunology and Microbiology | 8 | 11% |
| Biochemistry, Genetics and Molecular Biology | 7 | 9% |
| Chemistry | 3 | 4% |
| Other | 7 | 9% |
| Unknown | 16 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 September 2022.
All research outputs
#8,534,528
of 25,371,288 outputs
Outputs from Blood
#14,241
of 33,239 outputs
Outputs of similar age
#64,205
of 187,801 outputs
Outputs of similar age from Blood
#137
of 308 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 33,239 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,801 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 308 others from the same source and published within six weeks on either side of this one. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.